Boehringer Ingelheim invests €85 million in its new facility

| By | Boehringer Ingelheim, Drug Development, R&D

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on development activities for drugs in tablet form and manufacture them for worldwide market launches.

The pharmaceutical company is therefore investing 85 million in Ingelheim (Germany), focusing on modern and flexible production, to be even better positioned for marketing new, innovative drugs.

Starting in 2020, 75 employees will develop new production methods for tablet preparations and manufacture these centrally for all global market launches. In return, the production of older, easier-to-manufacture drugs has been gradually relocated to different countries in the worldwide manufacturing network since 2016, allowing greater focus on the more demanding tasks of chemical production.

The Solids Launch facility is an important piece of the puzzle, allowing Boehringer Ingelheim to keep the entire value-added chain in Germany over the long term, from research right through to production.

Between 2016 and 2017, Boehringer Ingelheim constructed a production facility in Ingelheim in record time, at a cost of 34 million – known as the “diabetes factory,” for innovative antidiabetic agents. As of 2020, the production of such preparations is to be relocated to other countries, such as Mexico and Greece. The facility was designed for flexibility and serves as a part of the new production strategy to prepare for product launches as well as be able to react promptly to market changes and develop products internally.